#BEGIN_DRUGCARD DB01160

# AHFS_Codes:
76:00.00

# ATC_Codes:
G02AD01

# Absorption:
Slowly absorbed from the amniotic fluid into systemic circulation.

# Biotransformation:
Enzymatic dehydrogenation primarily in the maternal lungs and also in the liver.

# Brand_Mixtures:
Not Available

# Brand_Names:
Dinolytic
Ensaprost
Lutalyse
Panacelan F tromethamine salt
Pronalgon F
Prostalmon F
Zinoprost

# CAS_Registry_Number:
38562-01-5

# ChEBI_ID:
Not Available

# Chemical_Formula:
C24H45NO8

# Chemical_IUPAC_Name:
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoic acid; 2-amino-2-(hydroxymethyl)propane-1,3-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
813605

# Description:
The tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha, dinoprost tromethamine occurs as a white to off-white, very hygroscopic, crystalline powder. Dinoprost tromethamine may also be known as dinoprost trometamol, PGF2 alpha THAM, or prostaglandin F2 alpha tromethamine.

# Dosage_Forms:
Solution	Intra-amniotic

# Drug_Category:
Abortifacient Agents, Nonsteroidal
Diagnostic aid (angiography)
Oxytocics
Uterine stimulants

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.12

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
0.2 g/mL

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Dinoprost Tromethamine

# HET_ID:
Not Available

# Half_Life:
The half-life of dinoprost in amniotic fluid is 3 to 6 hours. The plasma half-life of dinoprost after intravenous administration is reported to be less than 1 minute.

# InChI_Identifier:
InChI=1S/C20H34O5.C4H11NO3/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25;5-4(1-6,2-7)3-8/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25);6-8H,1-3,5H2/b7-4-,13-12+;/t15-,16+,17+,18-,19+;/m0./s1

# InChI_Key:
InChIKey=IYGXEHDCSOYNKY-RZHHZEQLSA-N

# Indication:
Used for aborting second-trimester pregnancy (between the twelfth to eighteenth week of gestation) and in incomplete abortion or for therapeutic abortion in cases of intrauterine fetal death and congenital abnormalities incompatible with life. Also used at low-doses for medically indicated induction of labor at term. Also injected intra-arterially for use as a vasodilator to assist in angiography.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D01352

# LIMS_Drug_ID:
1160

# Mechanism_Of_Action:
Dinoprost tromethamine appears to act directly on the myometrium, but this has not been completely established. Dinoprost stimulates myometrial contractions (via its interaction with the prostaglandin receptors) in the gravid uterus that are similar to the contractions that occur in the term uterus during labor. These contractions are usually sufficient to cause abortion. Uterine response to prostaglandins increases gradually throughout pregnancy. Dinoprost also facilitates cervical dilatation and softening.

# Melting_Point:
100 Â°C

# Molecular_Weight_Avg:
475.616

# Molecular_Weight_Mono:
475.314517421

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164781385

# Pharmacology:
Dinoprost tromethamine is the tromethamine (THAM) salt of the naturally occurring prostaglandin F2<sub>alpha</sub>. Prostaglandin F2<sub>alpha</sub>&nbsp;has several pharmacologic effects on the female reproductive system, including stimulation of myometrial activity, relaxation of the cervix, inhibition of steroidogenesis by corpora lutea, and can potentially lyse corpora lutea.

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB01160

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5282415

# PubChem_Substance_ID:
46509164

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00926

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OCC(N)(CO)CO.CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Dinoprost, trometamol salt
PGF2-alpha THAM
PGF2alpha THAM
Prostaglandin F2-alpha THAM
Prostaglandin F2a tromethamine
Prostaglandin F2alpha tham
Prostin F2 Alpha

# Synthesis_Reference:
Not Available

# Toxicity:
Although overdose by intra-amniotic administration of dinoprost has not been reported, exaggeration of the nausea, vomiting, and diarrhea that occur with normal doses would be expected.

# Update_Date:
2013-02-08 16:19:57 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
8777582	Sakamoto K, Kamimura M, Kurozumi S, Ito S: Prostaglandin F2 alpha receptor. J Lipid Mediat Cell Signal. 1995 Oct;12(2-3):405-11.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PTGFR

# Drug_Target_1_GenBank_ID_Gene:
L24470

# Drug_Target_1_GenBank_ID_Protein:
456564

# Drug_Target_1_GeneCard_ID:
PTGFR

# Drug_Target_1_Gene_Name:
PTGFR

# Drug_Target_1_Gene_Sequence:
>1080 bp
ATGTCCATGAACAATTCCAAACAGCTAGTGTCTCCTGCAGCTGCGCTTCTTTCAAACACA
ACCTGCCAGACGGAAAACCGGCTTTCCGTATTTTTTTCAGTAATCTTCATGACAGTGGGA
ATCTTGTCAAACAGCCTTGCCATCGCCATTCTCATGAAGGCATATCAGAGATTTAGACAG
AAGTCCAAGGCATCGTTTCTGCTTTTGGCCAGCGGCCTGGTAATCACTGATTTCTTTGGC
CATCTCATCAATGGAGCCATAGCAGTATTTGTATATGCTTCTGATAAAGAATGGATCCGC
TTTGACCAATCAAATGTCCTTTGCAGTATTTTTGGTATCTGCATGGTGTTTTCTGGTCTG
TGCCCACTTCTTCTAGGCAGTGTGATGGCCATTGAGCGGTGTATTGGAGTCACAAAACCA
ATATTTCATTCTACGAAAATTACATCCAAACATGTGAAAATGATGTTAAGTGGTGTGTGC
TTGTTTGCTGTTTTCATAGCTTTGCTGCCCATCCTTGGACATCGAGACTATAAAATTCAG
GCGTCGAGGACCTGGTGTTTCTACAACACAGAAGACATCAAAGACTGGGAAGATAGATTT
TATCTTCTACTTTTTTCTTTTCTGGGGCTCTTAGCCCTTGGTGTTTCATTGTTGTGCAAT
GCAATCACAGGAATTACACTTTTAAGAGTTAAATTTAAAAGTCAGCAGCACAGACAAGGC
AGATCTCATCATTTGGAAATGGTAATCCAGCTCCTGGCGATAATGTGTGTCTCCTGTATT
TGTTGGAGCCCATTTCTGGTTACAATGGCCAACATTGGAATAAATGGAAATCATTCTCTG
GAAACCTGTGAAACAACACTTTTTGCTCTCCGAATGGCAACATGGAATCAAATCTTAGAT
CCTTGGGTATATATTCTTCTACGAAAGGCTGTCCTTAAGAATCTCTATAAGCTTGCCAGT
CAATGCTGTGGAGTGCATGTCATCAGCTTACATATTTGGGAGCTTAGTTCCATTAAAAAT
TCCTTAAAGGTTGCTGCTATTTCTGAGTCACCAGTTGCAGAGAAATCAGCAAGCACCTAG

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
8300593	Abramovitz M, Boie Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM, Grygorczyk R: Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem. 1994 Jan 28;269(4):2632-6.

# Drug_Target_1_HGNC_ID:
HGNC:9600

# Drug_Target_1_HPRD_ID:
08988

# Drug_Target_1_ID:
672

# Drug_Target_1_Locus:
1p31.1

# Drug_Target_1_Molecular_Weight:
40055

# Drug_Target_1_Name:
Prostaglandin F2-alpha receptor

# Drug_Target_1_Number_of_Residues:
359

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Prostaglandin F2-alpha receptor
MSMNNSKQLVSPAAALLSNTTCQTENRLSVFFSVIFMTVGILSNSLAIAILMKAYQRFRQ
KSKASFLLLASGLVITDFFGHLINGAIAVFVYASDKEWIRFDQSNVLCSIFGICMVFSGL
CPLLLGSVMAIERCIGVTKPIFHSTKITSKHVKMMLSGVCLFAVFIALLPILGHRDYKIQ
ASRTWCFYNTEDIKDWEDRFYLLLFSFLGLLALGVSLLCNAITGITLLRVKFKSQQHRQG
RSHHLEMVIQLLAIMCVSCICWSPFLVTMANIGINGNHSLETCETTLFALRMATWNQILD
PWVYILLRKAVLKNLYKLASQCCGVHVISLHIWELSSIKNSLKVAAISESPVAEKSAST

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum

# Drug_Target_1_SwissProt_ID:
P43088

# Drug_Target_1_SwissProt_Name:
PF2R_HUMAN

# Drug_Target_1_Synonyms:
PGF receptor
PGF2 alpha receptor
Prostanoid FP receptor

# Drug_Target_1_Theoretical_pI:
9.11

# Drug_Target_1_Transmembrane_Regions:
32-54
70-90
110-131
153-175
199-224
251-267
286-307

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
PTGIR

# Drug_Target_2_GenBank_ID_Gene:
L29016

# Drug_Target_2_GenBank_ID_Protein:
495043

# Drug_Target_2_GeneCard_ID:
PTGIR

# Drug_Target_2_Gene_Name:
PTGIR

# Drug_Target_2_Gene_Sequence:
>1161 bp
ATGGCGGATTCGTGCAGGAACCTCACCTACGTGCGGGGCTCGGTGGGGCCGGCCACCAGC
ACCCTGATGTTCGTGGCCGGTGTGGTGGGCAACGGGCTGGCCCTGGGCATCCTGAGCGCA
CGGCGACCGGCGCGCCCCTCGGCCTTCGCGGTGCTGGTCACCGGACTGGCGGCCACCGAC
CTGCTGGGCACCAGCTTCCTGAGCCCGGCCGTGTTCGTGGCCTATGCGCGCAACAGCTCC
CTGCTGGGCCTGGCCCGAGGCGGCCCCGCCCTGTGCGATGCCTTCGCCTTCGCCATGACC
TTCTTCGGCCTGGCGTCCATGCTCATCCTCTTTGCCATGGCCGTGGAGCGCTGCCTGGCG
CTGAGCCACCCCTACCTCTACGCGCAGCTGGACGGGCCCCGCTGCGCCCGCCTGGCGCTG
CCAGCCATCTACGCCTTCTGCGTCCTCTTCTGCGCGCTGCCCCTGCTGGGCCTGGGCCAA
CACCAGCAGTACTGCCCCGGCAGCTGGTGCTTCCTCCGCATGCGCTGGGCCCAGCCGGGC
GGCGCCGCCTTCTCGCTGGCCTACGCCGGCCTGGTGGCCCTGCTGGTGGCTGCCATCTTC
CTCTGCAACGGCTCGGTCACCCTCAGCCTCTGCCGCATGTACCGCCAGCAGAAGCGCCAC
CAGGGCTCTCTGGGTCCACGGCCGCGCACCGGAGAGGACGAGGTGGACCACCTGATCCTG
CTGGCCCTCATGACAGTGGTCATGGCCGTGTGCTCCCTGCCTCTCACGATCCGCTGCTTC
ACCCAGGCTGTCGCCCCTGACAGCAGCAGTGAGATGGGGGACCTCCTTGCCTTCCGCTTC
TACGCCTTCAACCCCATCCTGGACCCCTGGGTCTTCATCCTTTTCCGCAAGGCTGTCTTC
CAGCGACTCAAGCTCTGGGTCTGCTGCCTGTGCCTCGGGCCTGCCCACGGAGACTCGCAG
ACACCCCTTTCCCAGCTCGCCTCCGGGAGGAGGGACCCAAGGGCCCCCTCTGCTCCTGTG
GGAAAGGAGGGGAGCTGCGTGCCTTTGTCGGCTTGGGGCGAGGGGCAGGTGGAGCCCTTG
CCTCCCACACAGCAGTCCAGCGGCAGCGCCGTGGGAACGTCGTCCAAAGCAGAAGCCAGC
GTCGCCTGCTCCCTCTGCTGA

# Drug_Target_2_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_2_General_References:
12488443	Miggin SM, Lawler OA, Kinsella BT: Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58. Epub 2002 Dec 17.
7512962	Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM, Abramovitz M: Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem. 1994 Apr 22;269(16):12173-8.
7514139	Katsuyama M, Sugimoto Y, Namba T, Irie A, Negishi M, Narumiya S, Ichikawa A: Cloning and expression of a cDNA for the human prostacyclin receptor. FEBS Lett. 1994 May 9;344(1):74-8.
7665161	Ogawa Y, Tanaka I, Inoue M, Yoshitake Y, Isse N, Nakagawa O, Usui T, Itoh H, Yoshimasa T, Narumiya S, et al.: Structural organization and chromosomal assignment of the human prostacyclin receptor gene. Genomics. 1995 May 1;27(1):142-8.
7923647	Nakagawa O, Tanaka I, Usui T, Harada M, Sasaki Y, Itoh H, Yoshimasa T, Namba T, Narumiya S, Nakao K: Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation. 1994 Oct;90(4):1643-7.

# Drug_Target_2_HGNC_ID:
HGNC:9602

# Drug_Target_2_HPRD_ID:
08959

# Drug_Target_2_ID:
527

# Drug_Target_2_Locus:
19q13.3

# Drug_Target_2_Molecular_Weight:
40956

# Drug_Target_2_Name:
Prostacyclin receptor

# Drug_Target_2_Number_of_Residues:
386

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Celecoxib Pathway	SMP00096
Etodolac Pathway	SMP00084
Meloxicam Pathway	SMP00106
Rofecoxib Pathway	SMP00087
Valdecoxib Pathway	SMP00116

# Drug_Target_2_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_2_Protein_Sequence:
>Prostacyclin receptor
MADSCRNLTYVRGSVGPATSTLMFVAGVVGNGLALGILSARRPARPSAFAVLVTGLAATD
LLGTSFLSPAVFVAYARNSSLLGLARGGPALCDAFAFAMTFFGLASMLILFAMAVERCLA
LSHPYLYAQLDGPRCARLALPAIYAFCVLFCALPLLGLGQHQQYCPGSWCFLRMRWAQPG
GAAFSLAYAGLVALLVAAIFLCNGSVTLSLCRMYRQQKRHQGSLGPRPRTGEDEVDHLIL
LALMTVVMAVCSLPLTIRCFTQAVAPDSSSEMGDLLAFRFYAFNPILDPWVFILFRKAVF
QRLKLWVCCLCLGPAHGDSQTPLSQLASGRRDPRAPSAPVGKEGSCVPLSAWGEGQVEPL
PPTQQSSGSAVGTSSKAEASVACSLC

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase

# Drug_Target_2_SwissProt_ID:
P43119

# Drug_Target_2_SwissProt_Name:
PI2R_HUMAN

# Drug_Target_2_Synonyms:
PGI receptor
Prostaglandin I2 receptor
Prostanoid IP receptor

# Drug_Target_2_Theoretical_pI:
8.53

# Drug_Target_2_Transmembrane_Regions:
17-38
52-76
95-115
135-158
182-208
236-260
275-295

#END_DRUGCARD DB01160
